Luke Bennett @LukeBennettFin

$CRDO – Credo Technology $CRDO is the pure high-speed connectivity play for AI data centers and it’s been growing at a ridiculous pace. Latest quarter: revenue of $479 million, up 115% year-over-year, with non-GAAP EPS of $1.20. Fiscal 2026 full-year revenue already hit roughly $1.3 billion, more than triple the prior year. They’re guiding Q2 revenue of $525–535 million and expecting full-year fiscal 2027 growth above 85%, with optical products alone targeted above $600 million. Gross margins remain strong and the balance sheet is clean. What could push it higher? Optical ramp accelerates as expected More hyperscaler design wins Continued sequential growth without margin collapse What could go wrong? Customer concentration risk AI CapEx pauses or slows Competition intensifies in AECs and optics My take: one of the cleaner high-growth AI infrastructure names right now. The numbers are already proving the demand; the question is how long the triple-digit growth can last. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. #CRDO #Stocks #StockMarket #StockTrading #AIStocks

A major AI company’s IPO filing often functions as a real-time check on how investors view the durability of infrastructure spending. That is what occurred Monday when Anthropic filed. The filing supported gains across AI-related stocks, with semiconductors participating and the major indexes closing higher. Today’s pre-market session is showing the typical next phase: selective rather than uniform follow-through. Memory stocks and certain semiconductor suppliers are the clearest beneficiaries so far. SK Hynix is higher on special dividend speculation, and Celestica has advanced after reporting results ahead of expectations and raising guidance. These moves show how company-specific news can reinforce a larger thematic bid. At the same time, the broader indexes are only modestly higher because the market still faces the Federal Reserve’s meeting that starts today and the Mag7 earnings later in the week. The practical observation is that relative strength inside the semiconductor and memory complex is currently the most consistent signal. It does not guarantee the indexes will follow, but it indicates where incremental capital is willing to go while the larger catalysts remain pending. How that relative strength behaves after the open will be more informative than the absolute level of the futures. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. #Stonks #AIBoom #Premarket #TSLA #NVDA #FedWatch

$TTMI +9.46% Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. Record Q3: revenue ~$1.2B (+60% YoY), strong EPS beat, margins expanding, driven by AI data-center and networking demand. Solid backlog, raised guidance, capacity expansion. Pure AI infrastructure beneficiary. I will share my unique market insights with you. I will share similar high-potential stocks with you daily. #TTMI #Stocks #StockMarket #StockTrading #AIStocks

Luke Bennett @LukeBennettFin

24 hours ago

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $T*** Expected Intraday Volatility: 10%–40% In the

0 0 0 139 0

$TTMI +9.46% Many group members followed my latest trading advice and made substantial profits Missed this opportunity? Don't worry!—Today is the last chance. Our community shares the following: Individual stock trends Key support and resistance levels Various market catalysts Short-term trading opportunities Private WhatsApp community—limited spots available. Join us to stay up-to-date with market movements. #TTMI #Stocks #QQQ #AIStocks

Luke Bennett @LukeBennettFin

24 hours ago

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $T*** Expected Intraday Volatility: 10%–40% In the

0 0 0 139 0

$CTKB +2.50% My prediction of the uptrend was absolutely correct—we are currently in an uptrend. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. Life-sciences tools — revenue beats / guidance raises, new product launches (Borealis 60-color cytometer, Aurora Evo), U.S./China demand recovery, and growing recurring revenue (service + reagents). Modest but steady upward pressure. #CTKB #Stocks #StockMarket #AIStocks

Luke Bennett @LukeBennettFin

24 hours ago

$CTKB Event/news background: Flow-cytometry company expanding cloud tools and clinical partnerships. Trading in the mid-$5s with the focus shifting toward profitability and recurring revenue. User personal behavior & expectations: On the watchlist. Want clearer proof that

0 0 1 112 0

@MarcJacksonLA Positive note from Stephens. They raised their price target on Cytek Biosciences to $6 (from $4.75) while maintaining an Overweight rating. $CTKB x.com/LukeBennettFin…

Luke Bennett @LukeBennettFin

24 hours ago

$CTKB Event/news background: Flow-cytometry company expanding cloud tools and clinical partnerships. Trading in the mid-$5s with the focus shifting toward profitability and recurring revenue. User personal behavior & expectations: On the watchlist. Want clearer proof that

0 0 1 112 0

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $T*** Expected Intraday Volatility: 10%–40% In the community, I will share: Entry Range Stop-Loss Level Real-Time Sell Alerts Daily Sharing of High-Quality Intraday Trading Opportunities. I focus on complete trade execution and risk control. Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. I will send you stock information. #Stock #QQQ #AIStock

Luke Bennett @LukeBennettFin

24 hours ago

$CTKB Event/news background: Flow-cytometry company expanding cloud tools and clinical partnerships. Trading in the mid-$5s with the focus shifting toward profitability and recurring revenue. User personal behavior & expectations: On the watchlist. Want clearer proof that

0 0 1 112 0

$CTKB Event/news background: Flow-cytometry company expanding cloud tools and clinical partnerships. Trading in the mid-$5s with the focus shifting toward profitability and recurring revenue. User personal behavior & expectations: On the watchlist. Want clearer proof that margins and reagent pull-through are actually improving before I get serious. Investment logic: Growing installed base in spectral flow cytometry. Reagents and software are the higher-margin opportunity. Upside drivers: Installed-base growth, reagent pull-through, margin expansion. Risk factors: Slowing growth, competition, execution on profits. Why it can run: Fair-value estimates have edged a bit higher toward ~$6. Short-term potential: Limited near-term catalysts. Overall potential: Steady if they convert the base into recurring revenue. Short-term target: low-to-mid $6s Summary: Show-me story on margins right now — patience required. Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. #CTKB #Biotech #Diagnostics #GrowthStocks #SmallCaps

Oil’s dropping hard this morning and futures are responding. Is this just a dead-cat bounce or the start of something better? Personally I think we need the mega-cap earnings to clear the AI ROI overhang before the market can really run. What are you watching most today? Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. #StockMarket #Fed #AI #OilPrices #Earnings #WallStreet

MONDAY’S WATCHLIST — BEFORE YOU HIT BUY The market is closed today, so there’s no fresh Sunday regular-session stock price to chase. Here’s what I’ll track when futures reopen: $SPY — Is the broader market stabilizing? $QQQ — Can tech regain momentum? $XLE — Does energy strength continue? $MSFT / $GOOGL / $AMZN — Earnings expectations and AI spending headlines. $VZ — Verizon reports Monday, making its outlook worth watching. I’ll also monitor crude oil and the 10-year Treasury yield for clues about risk appetite. My rule: Have a plan before the opening bell, not after a stock makes a big move. What’s your top ticker for Monday? Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. #Premarket #StockWatch #SPY #QQQ #TradingPlan #WallStreet

$QSI +21.30% Many group members followed my latest trading advice and made substantial profits Missed this opportunity? Don't worry!—Today is the last chance. Our community shares the following: Individual stock trends Key support and resistance levels Various market catalysts Short-term trading opportunities Private WhatsApp community—limited spots available. Join us to stay up-to-date with market movements. #QSI #Stocks #QQQ #AIStocks

Luke Bennett @LukeBennettFin

4 days ago

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $Q*** Expected Intraday Volatility: 10%–40% In the

0 0 0 286 0

$PHAR +6.09% My prediction of the uptrend was absolutely correct—we are currently in an uptrend. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. Pharming Group reported preliminary Q3 revenue of approximately $117.6M, up 21% YoY, and narrowed its full-year 2026 revenue guidance to $380M–$390M. That's a solid growth signal. Now comes the real test: the full report on October 27. I'm looking for product-level growth, operating expenses, cash flow, and management's outlook. Revenue growth is great—but profitable, sustainable growth is what investors really want. $PHAR an overlooked rare-disease pharma story? #PHAR #BiotechStocks #EarningsSeason #RareDiseases #PHARmaStocks

Luke Bennett @LukeBennettFin

4 days ago

$PHAR Pharming Group just gave investors a reason to take another look. Q3 2026 revenue is expected to reach approximately $117.6 million, up 21% year over year. Even better, management expects full-year revenue of $380 million–$390 million, while lowering its operating expense

0 0 1 334 0

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $Q*** Expected Intraday Volatility: 10%–40% In the community, I will share: Entry Range Stop-Loss Level Real-Time Sell Alerts Daily Sharing of High-Quality Intraday Trading Opportunities. I focus on complete trade execution and risk control. Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. I will send you stock information. #Stock #QQQ #AIStock

Luke Bennett @LukeBennettFin

4 days ago

$PHAR Pharming Group just gave investors a reason to take another look. Q3 2026 revenue is expected to reach approximately $117.6 million, up 21% year over year. Even better, management expects full-year revenue of $380 million–$390 million, while lowering its operating expense

0 0 1 334 0

$PHAR Pharming Group just gave investors a reason to take another look. Q3 2026 revenue is expected to reach approximately $117.6 million, up 21% year over year. Even better, management expects full-year revenue of $380 million–$390 million, while lowering its operating expense guidance. Here's why this matters: Pharming already has two commercial products generating revenue. This isn't a biotech company waiting for its first drug approval. RUCONEST, its treatment for acute hereditary angioedema attacks, generated approximately $93.8 million in Q3 revenue, up 14% year over year. But the more interesting growth story may be Joenja. Joenja revenue reached approximately $23.8 million, up 58% year over year, driven by growing U.S. patient numbers and international expansion, including Germany and Japan. The bigger opportunity is expanding leniolisib into broader immune-deficiency populations. If upcoming clinical trials support that strategy, Pharming could eventually address a much larger patient population than its current approved indication. The catalysts are real: Q3 2026 full financial results on October 27 Continued Joenja sales growth and international launches Expected November 2026 clinical data in CVID patients with immune dysregulation Progress toward a potential Phase III program in a broader patient population But there's a catch. RUCONEST still generates most of the company's revenue, so any weakness in its sales matters. International expansion doesn't guarantee commercial success, and new clinical trials bring regulatory, execution, and funding risks. Management has also tightened its full-year revenue guidance to $380 million–$390 million, representing approximately 1%–4% growth. That's a reminder that even a growing biotech can face pressure on its core business. My take: $PHAR is worth watching because it combines existing commercial revenue with meaningful pipeline catalysts. The bull case is that Joenja growth offsets RUCONEST pressure and creates a more diversified rare-disease business. The bear case is that clinical expansion takes longer and commercial growth fails to meet expectations. This is a 2–4-year execution story, with important near-term catalysts. I'd watch the upcoming earnings report and November clinical data before making assumptions about the upside. #PHAR #Biotech #PHARma #RareDisease #GrowthStocks #SmallCaps #NASDAQ

The Open-Bell Checklist Style: Fast-paced trader note Friday’s Open-Bell Checklist The premarket setup looks cautious, but the first move isn’t always the real move. Here’s my watchlist: QQQ: Does tech selling continue, or do buyers step in? SPY: Can the broader market stabilize after Thursday’s decline? XLE: Does higher crude support energy-sector momentum? CCI / AMT: Can telecom infrastructure strength survive the opening volatility? Treasury yields: Do economic data and inflation expectations change the rate outlook? I’m also watching opening volume and whether early breakouts hold their levels. No need to chase the first candle. Let the market show its hand. What ticker are you watching at 9:30 a.m. ET? Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. #PremarketTrading #OpeningBell #QQQ #SPY #StockWatch #DayTrader

$BHVN +36.26% My prediction of the uptrend was absolutely correct—we are currently in an uptrend. If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you. Biohaven’s licensing agreement with Ono Pharmaceutical covers its IgG degrader portfolio in Japan and select Asian markets. Reported deal terms include $80M upfront, up to $20M in near-term payments, and royalties. Why investors care: licensing deals can bring in cash without immediately issuing more shares, while adding external validation to a drug-development program. Still, clinical execution and milestone payments matter. Does this deal strengthen the long-term story for BHVN, or do you need more clinical proof first? Let’s break it down. #BHVN #BiotechStocks #PharmaDeals #DrugDevelopment #HealthcareInvesting

Luke Bennett @LukeBennettFin

5 days ago

$BHVN Biohaven is developing medicines across several therapeutic areas, including neurological and immunological diseases. One recent development stands out: On October 8, 2026, Biohaven signed a licensing agreement with Ono Pharmaceutical covering its extracellular IgG degrader

0 0 0 302 0

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket? In my private community, members receive complete trading strategies even before the market begins to fluctuate. Today's Alert: $T*** Expected Intraday Volatility: 10%–40% In the community, I will share: Entry Range Stop-Loss Level Real-Time Sell Alerts Daily Sharing of High-Quality Intraday Trading Opportunities. I focus on complete trade execution and risk control. Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information. I will send you stock information. #Stock #QQQ #AIStock

Luke Bennett @LukeBennettFin

5 days ago

$BHVN Biohaven is developing medicines across several therapeutic areas, including neurological and immunological diseases. One recent development stands out: On October 8, 2026, Biohaven signed a licensing agreement with Ono Pharmaceutical covering its extracellular IgG degrader

0 0 0 302 0

$BHVN Biohaven is developing medicines across several therapeutic areas, including neurological and immunological diseases. One recent development stands out: On October 8, 2026, Biohaven signed a licensing agreement with Ono Pharmaceutical covering its extracellular IgG degrader portfolio in Japan, South Korea, Taiwan, and Southeast Asia. The agreement includes an $80 million upfront payment and a potential additional $20 million milestone payment, plus royalties of approximately 20% on eligible regional net sales, subject to contractual adjustments. Ono will generally fund development and commercialization in the licensed territories. That's important because partnerships can provide non-dilutive funding and external validation of a drug-development platform. BHV-1300, the lead candidate in this portfolio, is in Phase 3 development for Graves' disease. But a licensing agreement does not establish that the drug will ultimately succeed. The bull case: The licensing deal brings in cash and potential royalties Clinical programs produce convincing results Partners help expand development and commercialization The company creates additional value from its broader pipeline The bear case is that clinical setbacks, high R&D spending, or delays prevent the pipeline from translating into commercial revenue. The key question is whether Biohaven can turn its broad development portfolio into successful medicines and sustainable economics. $BHVN is a pipeline-and-partnership story. The Ono deal is a meaningful development, but clinical execution remains the deciding factor. $BHVN #Biotech #Pharma #DrugDevelopment #HealthcareStocks